4-氨基-N-甲基咪唑-2-羧酸乙酯盐酸盐 | 180258-46-2

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物 - 羧酸酯及其衍生物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 4-氨基-N-甲基咪唑-2-羧酸乙酯盐酸盐
• 中文别名: 4-氨基-1-甲基-1H-咪唑2-羧酸乙酯盐酸盐；4 -氨基- 1 -甲基- 1H-咪唑2 -羧酸乙酯盐酸盐
• 英文名称: ethyl 4-amino-1-methyl-1H-imidazole-2-carboxylate hydrochloride
• 英文别名: ethyl 4-amino-1-methylimidazole-2-carboxylate;hydrochloride
• CAS: 180258-46-2
• 化学式: C₇H₁₁N₃O₂*ClH
• 分子量: 205.644
• InChiKey: CQRVNNMJJDJXPE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  70.1
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2933290090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  4-氨基-N-甲基咪唑-2-羧酸乙酯盐酸盐 在 sodium hydroxide 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 21.0h， 生成 4-叔丁氧羰基氨基-1-甲基-1H-咪唑-2-甲酸
  参考文献：
  名称：

  Solid Phase Synthesis of Polyamides Containing Imidazole and Pyrrole Amino Acids

  摘要：

  The solid phase synthesis of sequence specific DNA binding polyamides containing N-methylimidazole (Im) and N-methylpyrrole (Py) amino acids is described. Two monomer building blocks, Boc-Py-OBt ester and Boc-Im acid, are prepared on a 50 g scale without column chromatography. Using commercially available Boc-beta-alanine-Pam resin, cycling protocols were optimized to afford high stepwise coupling yields (>99%). Deprotection by aminolysis affords up to 100 mg quantities of polyamide. Solid phase methodology increases both the number and complexity of minor groove binding polyamides which can be synthesized and analyzed with regard to DNA binding affinity and sequence specificity. The solid phase synthesis of a representative eight-residue polyamide is reported.

  DOI：

  10.1021/ja960720z
• 作为产物：
  描述：

  1-甲基-4-硝基咪唑-2-羧酸乙酯 在 palladium-carbon 盐酸 、 氢气 作用下， 以 乙醚 、 乙醇 、 乙酸乙酯 为溶剂， 以78%的产率得到4-氨基-N-甲基咪唑-2-羧酸乙酯盐酸盐
  参考文献：
  名称：

  Complex formation between dsDNA and pyrrole imidazole polyamides

  摘要：

  提供了一种形成双链DNA与杂环、脂肪族氨基酸（特别是ω-氨基酸）和极性末端基团寡聚体复合物的方法和组合物。通过选择合适的靶序列和寡聚体的组成，可以获得具有低解离常数的复合物。复合物的形成可用于特定双链DNA序列的识别，用于抑制基因转录，并作为抑制不需要的细胞增殖或不需要的基因表达的治疗方法。

  公开号：

  US06143901A1

文献信息

• [EN] POLYCYCLIC AMIDES AS CYTOTOXIC AGENTS<br/>[FR] AMIDES POLYCYCLIQUES SERVANT D'AGENTS CYTOTOXIQUES
  申请人：FEMTOGENIX LTD

  公开号：WO2020049286A1

  公开（公告）日：2020-03-12

  The invention relates to a compound of formula (I): or pharmaceutically acceptable salts, solvates, tautomers, stereoisomers or mixtures thereof; wherein the fused ring moiety is a non-alkylating moiety; and wherein the compounds are useful as medicaments, in particular for use as a drug in an antibody-drug conjugate and in the treatment of a proliferative disease, a bacterial infection, a malarial infection and inflammation.

  该发明涉及公式(I)的化合物；或其药学上可接受的盐、溶剂合物、互变异构体、立体异构体或它们的混合物；其中融合环基团是非烷基化基团；这些化合物可用作药物，特别是用作抗体药物结合物中的药物，以及用于治疗增殖性疾病、细菌感染、疟疾感染和炎症。
• Substituted quinazoline derivatives and their use as inhibitors
  申请人：AstraZeneca AB

  公开号：US20030187002A1

  公开（公告）日：2003-10-02

  The use of a compound of formula (I) 1 or a salt, ester or amide thereof; where X is O, or S, S(O) or S(O) 2 , or NR 6 where R 6 is hydrogen or C 1-6 alkyl,; R 5 is an optionally substituted 5-membered heteroaromatic ring, R 1 , R 2 , R 3 , R 4 are independently selected from various specified moieties, in the preparation of a medicament for use in the inhibition of aurora 2 kinase. Certain compounds are novel and these, together with pharmaceutical compositions containing them are also described and claimed.

  使用式(I)的化合物或其盐、酯或酰胺； 其中X为O、S、S(O)或S(O)2，或NR6，其中R6为氢或C1-6烷基； R5为可选择取代的5-成员杂芳环， R1、R2、R3、R4分别选自各种指定的基团，在制备用于抑制aurora 2激酶的药物中使用。 某些化合物是新颖的，这些化合物以及含有它们的药物组合物也有描述和声明。
• [EN] PIPERIDINOBENZODIAZEPINE COMPOUNDS WITH ANTI PROLIFERATIVE ACTIVITY<br/>[FR] COMPOSÉS DE PIPÉRIDINOBENZODIAZÉPINE AYANT UNE ACTIVITÉ ANTI-PROLIFÉRATIVE
  申请人：FEMTOGENIX LTD

  公开号：WO2017032983A1

  公开（公告）日：2017-03-02

  The invention relates to pyrridinobenzodiazepines (PDDs) comprising three fused 6-7-6-membered rings linked to aromatic groups, and pharmaceutically acceptable salts thereof, which are useful as medicaments, such as anti-proliferative agents. PDDs may be represented by formula (I): and salts and solvates thereof, wherein the dotted lines indicates the optional presence of a double bond between one or more of Ci and C2, C2and C3, and C3and C4; R1 and R2 are substituent groups; R3 is selected from H, C1-12 alkyl and CH2Ph; R4is selected from phenyl and C5-9heteroaryl groups optionally substituted, with the proviso that the optionally substituted C5-9heteroaryl is not indolyl; R19is selected from H and (CH2)t-NR20R21; Yiis N or CH; Y2 is N or CH; and wherein at least one of Y1and Y2 is CH; p is o or1; X1 is a connecting group; L is a linker group; X2 is a connecting group or is absent; q is selected from o,1, 2, 3,4,5and 6; A is selected from: for each Ai group one of Y3and Y4is selected from N-R17,S and O; and the other of Y3and Y4is CH; and Y5is selected from CH, N, S and COH; for each A2group one of Y6and Y7is independently selected from N and CH; and the other of Y6and Y7is CH; R13, R14, R17, R2oand R2iare independently selected from H and C1-6alkyl; and either: (i) R5and R6together form a double bond; (ii) R5is H and R6is OH; or (iii) R5is H and R6is OC1-6alkyl; with the proviso that when p is o and A is Ai, then: (a) for at least one Ai group one of Y3and Y4is selected from S and O; or (b) for at least one Ai group Y5is S; or (c) R4is not pyrrolyl, imidazolyl, optionally substituted pyrrolyl or optionally substituted imidazolyl.

  该发明涉及含有与芳香族基团连接的三个融合的6-7-6环的吡啶苯二氮䓬（PDDs）及其药学上可接受的盐，这些化合物可用作药物，如抗增殖剂。 PDDs可以用公式（I）表示：及其盐和溶剂化合物，其中虚线表示Ci和C2，C2和C3以及C3和C4中的一个或多个之间的双键的可选存在；R1和R2是取代基；R3从H，C1-12烷基和CH2Ph中选择；R4从苯基和C5-9杂环基团中选择，可选择地取代，但有条件的是可选择地取代的C5-9杂环基团不是吲哚基；R19从H和（CH2）t-NR20R21中选择；Yi是N或CH；Y2是N或CH；其中Y1和Y2中至少一个是CH；p是o或1；X1是连接基团；L是连接基团；X2是连接基团或不存在；q从o，1，2，3，4，5和6中选择；A从以下中选择：对于每个Ai基团，Y3和Y4中的一个从N-R17，S和O中选择；另一个从CH中选择；Y5从CH，N，S和COH中选择；对于每个A2基团，Y6和Y7中的一个独立地从N和CH中选择；另一个是CH；R13，R14，R17，R2o和R2i独立地从H和C1-6烷基中选择；并且：（i）R5和R6一起形成双键；（ii）R5是H，R6是OH；或（iii）R5是H，R6是OC1-6烷基；但有条件的是当p是o且A是Ai时，那么：（a）对于至少一个Ai基团，Y3和Y4中的一个从S和O中选择；或（b）对于至少一个Ai基团，Y5是S；或（c）R4不是吡咯基，咪唑基，可选择地取代的吡咯基或可选择地取代的咪唑基。
• Benzoisothiazolone Organo/Copper-Cocatalyzed Redox Dehydrative Construction of Amides and Peptides from Carboxylic Acids using (EtO)₃P as the Reductant and O₂ in Air as the Terminal Oxidant
  作者：Lanny S. Liebeskind、Pavankumar Gangireddy、Matthew G. Lindale

  DOI：10.1021/jacs.6b03168

  日期：2016.6.1

  Carboxylic acids and amine/amino acid reactants can be converted to amides and peptides at neutral pH within 5-36 h at 50 °C using catalytic quantities of a redox-active benzoisothiazolone and a copper complex. These catalytic "oxidation-reduction condensation" reactions are carried out open to dry air using O2 as the terminal oxidant and a slight excess of triethyl phosphite as the reductant. Triethyl

  使用催化量的具有氧化还原活性的苯并异噻唑酮和铜络合物，羧酸和胺/氨基酸反应物可以在 50°C 下在 5-36 小时内在中性 pH 值下转化为酰胺和肽。这些催化“氧化-还原缩合”反应在干燥空气中进行，使用O 2 作为末端氧化剂和稍微过量的亚磷酸三乙酯作为还原剂。磷酸三乙酯是容易去除的副产物。这些易于运行的催化反应为 CN 键的酰化构建提供了实用且经济的方法。
• Guanidiniocarbonyl-pyrrole-aryl conjugates as nucleic acid sensors: switch of binding mode and spectroscopic responses by introducing additional binding sites into the linker
  作者：Kathrin Gröger、Domagoj Baretić、Ivo Piantanida、Marko Marjanović、Marijeta Kralj、Marina Grabar、Sanja Tomić、Carsten Schmuck

  DOI：10.1039/c0ob00103a

  日期：——

  Two novel guanidiniocarbonyl pyrrole–pyrene conjugates 3 and 4 as spectroscopic probes for ds-polynucleotides were synthesized and their interaction with different ds-DNAs/RNAs studied. Compared to a previously reported first set of conjugates (1 and 2) the significant extension and increased rigidity of the central part of the structure resulted in a switch of DNA binding mode from intercalative (previously studied derivatives 1 and 2 with a nonbinding and flexible linker) to minor groove binding of the two novel guanidiniocarbonyl-pyrrole–pyrene conjugates 3 and 4. These two compounds interact strongly with ds-DNAs, but only weakly with ds-RNA. The newly incorporated heterocyclic moieties within the central part of the structure of 3 and 4 were able to control by steric and hydrogen-bonding effects the alignment of the molecules within various, structurally different forms of DNA minor grooves, whereby even small differences in the position of the attached pyrene within the groove were reflected in different fluorimetric responses. In addition, 3 and 4 revealed intriguing in vitro selectivity among various human tumour cell lines.

  合成了两种新型胍基羰基吡咯-芘缀合物 3 和 4 作为双链多核苷酸的光谱探针，并研究了它们与不同双链 DNA/RNA 的相互作用。与之前报道的第一组缀合物（1和2）相比，结构中心部分的显着延伸和刚性增加导致DNA结合模式从插入式转变（之前研究的具有非结合和柔性接头的衍生物1和2） ）与两种新型胍基羰基-吡咯-芘缀合物 3 和 4 的小沟结合。这两种化合物与 ds-DNA 相互作用强烈，但与 ds-RNA 相互作用较弱。 3和4结构中心部分新掺入的杂环部分能够通过空间和氢键作用控制分子在各种结构不同形式的DNA小沟内的排列，从而即使位置上的微小差异凹槽内附着的芘的变化反映在不同的荧光响应中。此外，3和4揭示了各种人类肿瘤细胞系之间有趣的体外选择性。